{"id":"W3025530165","doi":"10.1007/s13555-020-00383-x","title":"Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)","year":2020,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":39,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Eli Lilly and Company","keywords":"Medicine; Psoriasis; Ixekizumab; Dermatology; Nail (fastener); Psoriasis Area and Severity Index; Ustekinumab; Plaque psoriasis; Internal medicine; Secukinumab; Psoriatic arthritis; Disease; Adalimumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023759,0.0007044137,0.00154548,0.0002269449,0.0002717996,0.000597944,0.0004155639,0.0006386787,0.003032089],"category_scores_gemma":[0.001031961,0.0003656423,0.001518828,0.0002745528,0.0005333275,0.000464832,0.0002756071,0.00155,0.000468793],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004017875,"about_ca_system_score_gemma":0.0007916904,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000847443,"about_ca_topic_score_gemma":0.001783172,"domain_scores_codex":[0.9992823,0.0004071926,0.00004776061,0.0000734425,0.00008193198,0.0001073522],"domain_scores_gemma":[0.9991497,0.0001879006,0.0001818104,0.00007975142,0.00005611459,0.0003448471],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8113439,0.04002262,0.01299268,0.0009535122,0.002279046,0.0001353412,0.0002956585,0.0008145996,0.02972844,0.00008068222,0.002064837,0.09928873],"study_design_scores_gemma":[0.4879314,0.4431097,0.06293894,0.00006139858,0.0009633857,0.0003268489,0.00007392422,0.0004849301,0.002734751,0.00007904309,0.001263139,0.00003263001],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9968835,0.001570101,0.0001467861,0.0001043508,0.00002500398,0.0004040819,0.0002163805,0.00003126421,0.0006185423],"genre_scores_gemma":[0.9964295,0.001022104,0.0005032351,0.0003085701,0.00009471324,0.0003330061,0.0004070601,0.000009692597,0.0008922276],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003032089,"threshold_uncertainty_score":0.01256514,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02972612552435288,"score_gpt":0.266550465056885,"score_spread":0.2368243395325321,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}